Theriva Biologics (TOVX) EBITDA Margin (2010 - 2026)

Theriva Biologics (TOVX) posted quarterly EBITDA Margin of 709.0% for Q1 2026, down 347.21% quarter-over-quarter from 286.8% in Q4 2011.

Theriva Biologics (TOVX) EBITDA Margin (2010 - 2026) Analysis & Trends

Theriva Biologics (TOVX) has reported EBITDA Margin for 3 consecutive years, with 709.0% the latest figure, recorded in Q1 2026.

In Q1 2026, EBITDA Margin changed N/A year-over-year to 709.0%; the TTM figure through Mar 2026 stood at 94053.07% (changed N/A YoY), while the FY2010 annual figure was 2.1%, changed N/A from the prior year.
EBITDA Margin declined to 709.0% in Q1 2026 per TOVX's latest filing, from 286.8% in the prior quarter.
Across five years, EBITDA Margin topped out at 709.0% in Q1 2026 and bottomed at 709.0% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBITDA Margin (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	37.40%
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	30.15%
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	32.54%
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-562.07%
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	19.06%
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	17.93%
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-35.57%
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-0.36%
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	19.75%
10	Theriva Biologics	10.64 Mn	10.64 Mn	-	-

Download Data